Domača stranGNLX • NASDAQ
add
Genelux Corp
2,96 $
Po zaprtju:(4,73 %)−0,14
2,82 $
Konec trgovanja: 9. maj, 18:53:23 GMT -4 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
2,85 $
Dnevni razpon
2,69 $ - 3,05 $
Letni razpon
1,60 $ - 5,89 $
Tržna kapitalizacija
111,70 mio. USD
Povprečni obseg
188,29 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | mar. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | — | — |
Stroški poslovanja | 7,82 mio. | −3,78 % |
Čisti dohodek | −7,49 mio. | 4,56 % |
Čista dobičkovnost prihodkov | — | — |
Earnings per share | −0,21 | 27,59 % |
EBITDA | −7,76 mio. | 3,41 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | mar. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 35,10 mio. | 78,85 % |
Skupna sredstva | 38,98 mio. | 57,99 % |
Skupne obveznosti | 9,14 mio. | −4,72 % |
Celoten lastniški kapital | 29,85 mio. | — |
Shares outstanding | 37,73 mio. | — |
Razmerje P/B | 3,61 | — |
Donosnost sredstev | −53,02 % | — |
Donosnost kapitala | −65,38 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | mar. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −7,49 mio. | 4,56 % |
Denar iz dejavnosti | −5,44 mio. | −24,83 % |
Denar iz naložb | 3,51 mio. | 307,51 % |
Denar iz financiranja | 9,57 mio. | 1.290,55 % |
Neto sprememba denarnih sredstev | 7,64 mio. | 242,64 % |
Prost denarni tok | −4,19 mio. | −220,46 % |
Vizitka
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Datum ustanovitve
2001
Sedež organizacije
Spletno mesto
Zaposleni
24
